A Phase 2B, Dose-Ranging, Randomized, Double-Blind, Placebo- Controlled Trial Evaluating the Safety and Efficacy of GS-6624, A Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects with Advanced Liver Fibrosis But Not Cirrhosis Secondary To Non-Alcoholic Steatohepatitis (NASH)
Principal Investigator(s)
Email for information
Funded by
Geneva Foundation
Research Start Date
Status
Active
This study will evaluate whether simtuzumab (formerly referred to as GS-6624) is effective at preventing the histologic progression of liver fibrosis and the clinical progression to cirrhosis in participants with non-alcoholic steatohepatitis (NASH).
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.